_ OUR NEWS
OCULUS BIOMED NEWS
June 2, 2021
Oculus Biomed Limited (“OBM”) is pleased to announce the European patent application which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular […]
May 3, 2021
Oculus Biomed Limited (“OBM”) is pleased to announce the application of the Chinese Patent which covers its OBM-1701 has been allowed. The term of the Chinese […]
January 8, 2021
Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers its OBM- 17xx. The term of the Chinese patent extend […]
July 1, 2020
Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Mackay Memorial Hospital (“MMH”), in Taipei, Taiwan. Established on 26 December […]
May 15, 2020
Oculus Biomed Limited (“OBM”) announces that it had requested to terminate the acquisition discussion with Lanka Graphite Limited (“LGR”) (ASX:LGR), effective immediately. OBM has no further […]
February 18, 2020
Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered into a non-binding Heads of Agreement (“HOA”) with Lanka Graphite Limited (“LGR”) (ASX: LGR). […]